WAVE Life Sciences Ltd. (WVE) Now Covered by HC Wainwright

WAVE Life Sciences Ltd. (WVE) Now Covered by HC Wainwright

305
0
SHARE

Analysts at HC Wainwright started coverage on shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating and a $41.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 36.67% from the company’s current price.

Several other brokerages also recently commented on WVE. Jefferies Group LLC set a $42.00 price objective on shares of WAVE Life Sciences and gave the stock a “buy” rating in a research report on Tuesday, December 13th. JMP Securities reaffirmed a “buy” rating on shares of WAVE Life Sciences in a research report on Thursday, November 10th. Zacks Investment Research raised shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 17th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $45.00 price objective on shares of WAVE Life Sciences in a research report on Thursday, November 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $36.60.

WAVE Life Sciences (NASDAQ:WVE) opened at 30.00 on Wednesday. WAVE Life Sciences has a one year low of $11.99 and a one year high of $40.15. The company’s 50-day moving average is $28.30 and its 200-day moving average is $29.07. The firm’s market capitalization is $704.25 million.

This report was published by [[site]] and is the property of of [[site]]. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international copyright law. The correct version of this report can be accessed at [[permalink]].

Several hedge funds have recently made changes to their positions in the company. New Leaf Venture Partners L.L.C. purchased a new position in shares of WAVE Life Sciences during the fourth quarter worth about $17,213,000. Eventide Asset Management LLC boosted its position in shares of WAVE Life Sciences by 1.0% in the fourth quarter. Eventide Asset Management LLC now owns 383,630 shares of the company’s stock worth $10,032,000 after buying an additional 3,630 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of WAVE Life Sciences during the fourth quarter worth about $403,000. Marshall Wace LLP purchased a new position in shares of WAVE Life Sciences during the fourth quarter worth about $780,000. Finally, FMR LLC boosted its position in shares of WAVE Life Sciences by 1.7% in the fourth quarter. FMR LLC now owns 1,893,756 shares of the company’s stock worth $49,522,000 after buying an additional 31,907 shares in the last quarter. 59.83% of the stock is owned by institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

5 Day Chart for NASDAQ:WVE

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

SHARE
Dan specializes in matters of money management and personal finance and has been published on numerous financial, business, health and wellness and sports websites.

LEAVE A REPLY